Ever Supreme Bio Technology Co., Ltd (TPEX:6712)
Taiwan
· Delayed Price · Currency is TWD 129.00
0.00 (0.00%)
Apr 29, 2026, 1:30 PM CST
TPEX:6712 Revenue
In the year 2025, Ever Supreme Bio Technology had annual revenue of 1.02B TWD with 8.96% growth. Ever Supreme Bio Technology had revenue of 355.39M in the quarter ending December 31, 2025, with 3.33% growth.
Revenue
1.02B
Revenue Growth
+8.96%
P/S Ratio
11.11
Revenue / Employee
n/a
Employees
94
Market Cap
11.30B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.02B | 83.69M | 8.96% |
| Dec 31, 2024 | 933.81M | 175.42M | 23.13% |
| Dec 31, 2023 | 758.39M | 130.88M | 20.86% |
| Dec 31, 2022 | 627.51M | 188.67M | 42.99% |
| Dec 31, 2021 | 438.84M | 368.24M | 521.61% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CHO Pharma | 1.43M |
| Tanvex BioPharma | 400.97M |
| Locus Cell | 12.74M |
| TaiMed Biologics | 611.35M |
| EirGenix | 1.01B |
| Gongwin Biopharm Holdings | 36.45M |
| Polaris Group | 40.60M |
| Medigen Vaccine Biologics | 613.17M |